Pharmacotherapeutics for
Advanced Practice Nurse
Prescribers with Davis Edge
6th Edition
• Author(s)Teri Moser Woo; Wendy
L. Wright
TEST BANK
▪ The Foundation
▪ Pharmacotherapeutics with Single Drugs
▪ Pharmacotherapeutics with Multiple Drugs
▪ Special Drug Treatment Considerations
,Question 1
A family nurse practitioner (FNP) is preparing to prescribe an
antihypertensive medication for a 58-year-old patient with newly
diagnosed stage 2 hypertension. The patient asks whether the
prescription can be filled with a less expensive generic product instead
of the brand-name medication. Which response by the APRN best
reflects evidence-based prescribing practice?
A. Generic medications should be avoided because they are less
effective than brand-name medications.
B. Generic medications approved by the U.S. Food and Drug
Administration (FDA) are expected to provide comparable safety,
quality, and therapeutic effect to the brand-name product.
C. Generic medications should only be used if the patient has no
prescription drug insurance.
D. Generic medications are appropriate only for short-term treatment.
Correct Answer: B
Rationale:
FDA-approved generic medications must demonstrate bioequivalence
and meet rigorous standards for quality, strength, purity, and
performance. In most clinical situations, they provide therapeutic
outcomes comparable to brand-name products while reducing patient
costs, which may improve adherence. Option A is incorrect because
generic drugs are not considered inherently less effective. Option C
incorrectly limits generic use to financial circumstances. Option D is
inaccurate because generics are appropriate for both acute and chronic
conditions when clinically suitable.
,Question 2
An adult-gerontology primary care nurse practitioner (AGPCNP)
evaluates a 72-year-old patient with type 2 diabetes mellitus and
hypertension. Before prescribing a new medication, which action is
most important to reduce the risk of medication-related harm?
A. Prescribe the medication with the lowest acquisition cost.
B. Review the patient's complete medication list, including over-the-
counter medications and herbal supplements.
C. Begin therapy with the maximum recommended dose to achieve
faster control.
D. Delay treatment until laboratory results are available for every
chronic condition.
Correct Answer: B
Rationale:
Medication reconciliation is a fundamental component of safe
prescribing. Reviewing prescription medications, over-the-counter
products, vitamins, and herbal supplements helps identify drug
interactions, duplicate therapies, contraindications, and adherence
concerns before initiating treatment. Option A considers cost but does
not adequately address safety. Option C increases the risk of adverse
effects and is inconsistent with individualized dosing principles. Option
D may unnecessarily delay appropriate treatment when immediate
therapy is clinically indicated.
Question 3
, A psychiatric-mental health nurse practitioner (PMHNP) is considering
initiating pharmacotherapy for a patient with major depressive
disorder. The patient reports taking an herbal supplement purchased
online to improve mood but cannot remember its name. What is the
best initial prescribing action?
A. Proceed with the prescription because dietary supplements rarely
interact with prescription medications.
B. Advise the patient to discontinue all supplements permanently.
C. Identify the specific supplement before prescribing because some
herbal products have clinically significant drug interactions.
D. Delay treatment for depression indefinitely until all supplements are
discontinued.
Correct Answer: C
Rationale:
Many herbal and dietary supplements may alter drug metabolism or
pharmacologic effects, increasing the risk of adverse reactions or
treatment failure. Obtaining a complete medication history, including
supplements, supports safe prescribing and individualized care. Option
A underestimates the potential for clinically important interactions.
Option B may not be appropriate without knowing the specific product
or clinical context. Option D unnecessarily postpones treatment when
safe management strategies are available.
Question 4
A women's health nurse practitioner (WHNP) is preparing to prescribe
an oral medication for a patient of reproductive age. Which assessment
Advanced Practice Nurse
Prescribers with Davis Edge
6th Edition
• Author(s)Teri Moser Woo; Wendy
L. Wright
TEST BANK
▪ The Foundation
▪ Pharmacotherapeutics with Single Drugs
▪ Pharmacotherapeutics with Multiple Drugs
▪ Special Drug Treatment Considerations
,Question 1
A family nurse practitioner (FNP) is preparing to prescribe an
antihypertensive medication for a 58-year-old patient with newly
diagnosed stage 2 hypertension. The patient asks whether the
prescription can be filled with a less expensive generic product instead
of the brand-name medication. Which response by the APRN best
reflects evidence-based prescribing practice?
A. Generic medications should be avoided because they are less
effective than brand-name medications.
B. Generic medications approved by the U.S. Food and Drug
Administration (FDA) are expected to provide comparable safety,
quality, and therapeutic effect to the brand-name product.
C. Generic medications should only be used if the patient has no
prescription drug insurance.
D. Generic medications are appropriate only for short-term treatment.
Correct Answer: B
Rationale:
FDA-approved generic medications must demonstrate bioequivalence
and meet rigorous standards for quality, strength, purity, and
performance. In most clinical situations, they provide therapeutic
outcomes comparable to brand-name products while reducing patient
costs, which may improve adherence. Option A is incorrect because
generic drugs are not considered inherently less effective. Option C
incorrectly limits generic use to financial circumstances. Option D is
inaccurate because generics are appropriate for both acute and chronic
conditions when clinically suitable.
,Question 2
An adult-gerontology primary care nurse practitioner (AGPCNP)
evaluates a 72-year-old patient with type 2 diabetes mellitus and
hypertension. Before prescribing a new medication, which action is
most important to reduce the risk of medication-related harm?
A. Prescribe the medication with the lowest acquisition cost.
B. Review the patient's complete medication list, including over-the-
counter medications and herbal supplements.
C. Begin therapy with the maximum recommended dose to achieve
faster control.
D. Delay treatment until laboratory results are available for every
chronic condition.
Correct Answer: B
Rationale:
Medication reconciliation is a fundamental component of safe
prescribing. Reviewing prescription medications, over-the-counter
products, vitamins, and herbal supplements helps identify drug
interactions, duplicate therapies, contraindications, and adherence
concerns before initiating treatment. Option A considers cost but does
not adequately address safety. Option C increases the risk of adverse
effects and is inconsistent with individualized dosing principles. Option
D may unnecessarily delay appropriate treatment when immediate
therapy is clinically indicated.
Question 3
, A psychiatric-mental health nurse practitioner (PMHNP) is considering
initiating pharmacotherapy for a patient with major depressive
disorder. The patient reports taking an herbal supplement purchased
online to improve mood but cannot remember its name. What is the
best initial prescribing action?
A. Proceed with the prescription because dietary supplements rarely
interact with prescription medications.
B. Advise the patient to discontinue all supplements permanently.
C. Identify the specific supplement before prescribing because some
herbal products have clinically significant drug interactions.
D. Delay treatment for depression indefinitely until all supplements are
discontinued.
Correct Answer: C
Rationale:
Many herbal and dietary supplements may alter drug metabolism or
pharmacologic effects, increasing the risk of adverse reactions or
treatment failure. Obtaining a complete medication history, including
supplements, supports safe prescribing and individualized care. Option
A underestimates the potential for clinically important interactions.
Option B may not be appropriate without knowing the specific product
or clinical context. Option D unnecessarily postpones treatment when
safe management strategies are available.
Question 4
A women's health nurse practitioner (WHNP) is preparing to prescribe
an oral medication for a patient of reproductive age. Which assessment
